Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,419 shares of the medical research company's stock, valued at approximately $1,212,000.
A number of other hedge funds have also made changes to their positions in TMO. High Note Wealth LLC increased its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $28,000. Kilter Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $25,000. Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after acquiring an additional 22 shares during the last quarter. Finally, Birchwood Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. 89.23% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Thermo Fisher Scientific
In related news, VP Lisa P. Britt sold 11,440 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. This trade represents a 7.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by company insiders.
Thermo Fisher Scientific Trading Down 1.4%
Shares of Thermo Fisher Scientific stock opened at $621.87 on Friday. The company has a market cap of $229.94 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 2.53 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The company's fifty day simple moving average is $558.64 and its 200-day simple moving average is $512.08. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the firm earned $4.28 EPS. The business's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is currently 10.11%.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on the company. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their price objective for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Barclays increased their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Finally, Royal Bank Of Canada boosted their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $619.41.
View Our Latest Research Report on TMO
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
